GBMs are aggressive tumors and despite improvements in treatment regimens, which include surgical resection, radiation, and chemotherapy, prognosis is poor with a median survival of 14.6 months[2] Research has indicated that the genomes of GBMs have multiple changes including deletion of tumor suppressor genes and amplification or over-expression of tyrosine kinase receptors leading to both survival advantage and apoptosis resistance in tumor cells. The gene discussed is NTRK1; the disease is neoplasm.